Ceryvyn Therapeutics Ltd. - Unsponsored ADR CYVNY
0.02
0.00
0.00%
as of 24 Sep
- Market cap
- $524.8M
- P/E
- 0.0×
Follow CYVNY
| Jun '16 | Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 332.48 | 225.61 | 404.91 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (65.78) | (4.77) | (2.42) | (0.64) | (0.32) | (0.59) |
P/B ratio |
— | — | — | — | 11.53 | 1.61 | 3.59 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | 11.53 | 1.61 | 3.59 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | 0.00 | 0.00 | 0.00 | 317.97 | 347.87 | 1,161.82 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (17.20) | (1.48) | (0.78) | (0.25) | (0.19) | (0.58) |
EV/FCF |
— | — | — | — | (17.20) | (1.48) | (0.79) | (0.25) | (0.19) | (0.58) |
Quick Ratio |
8.18 | 27.55 | 5.71 | 5.60 | 10.24 | 39.83 | 4.25 | 5.11 | 2.88 | 0.22 |
Current Ratio |
8.27 | 27.63 | 5.75 | 5.66 | 10.31 | 44.46 | 4.98 | 5.25 | 2.94 | 0.22 |
Net Debt/EBITDA |
1.80 | 5.26 | 1.09 | 0.58 | 2.57 | 2.98 | 0.46 | 0.02 | (0.15) | 0.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.17% | 0.00% | 0.00% | 86.93% | 106.22% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (14.65) | (2.65) | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.57 | 0.98 | 1.18 | 1.16 | 0.51 | 1.00 | 0.77 | 0.85 | 0.73 | 0.97 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (18.24%) | (17.96%) | (35.67%) | (58.45%) | (33.54%) | (50.42%) | (101.29%) | (676.68%) | 539.40% | 117.59% | |
| (17.23%) | (75.13%) | (73.37%) | (48.37%) | (29.36%) | (48.28%) | (93.54%) | (179.62%) | (153.25%) | (132.57%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (517.79%) | (144.96%) | (1,803.34%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(44.19%) | (11.60%) | (45.17%) | (68.71%) | (25.10%) | (33.58%) | (193.79%) | (178.87%) | (177.35%) | 80.96% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 37,449.25 | 29,467.10 | 26,387.05 | 22,098.33 | 34,526.08 | 111,047.60 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 20,412.86% | 37,743.29% | 86,719.07% | 118,845.85% | 141,060.80% | 507,328.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 7,957.53% | 19,533.24% | 19,760.09% | 19,909.78% | 12,622.40% | 116,304.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | 0.11 | 0.62 | 0.28 | (0.08) | (1.47) | (2.16) |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (0.74%) | (1.94%) | (3.61%) | (16.96%) | (25.00%) | (13.93%) |
Free Cash Flow Yield |
— | — | — | — | (5.18%) | (30.74%) | (94.23%) | (378.65%) | (808.72%) | (494.89%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | (0.20) | (0.51) | (0.52) | (0.17) | (1.14) | (1.62) | (2.18) | (2.02) | (1.04) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.00 | (0.20) | (0.51) | (0.52) | (0.16) | (1.12) | (1.62) | (2.18) | (2.02) | (1.04) |
Cash per Share |
0.00 | 1.72 | 0.83 | 0.46 | 1.31 | 2.95 | 1.02 | 1.61 | 2.16 | 0.32 |
Shareholders Equity per Share |
0.00 | 1.80 | 0.97 | 0.67 | 1.37 | 3.38 | 1.09 | (0.11) | (0.95) | (1.31) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 1.80 | 0.97 | 0.67 | 1.37 | 3.38 | 1.09 | (0.11) | (0.95) | (1.31) |
Free Cash Flow |
(2.74) | (4.65) | (14.77) | (16.91) | (5.36) | (44.89) | (71.35) | (120.63) | (161.05) | (158.66) |
Working Capital |
10.88 | 41.02 | 27.67 | 21.24 | 44.29 | 135.01 | 47.87 | 79.64 | 124.14 | (201.07) |
Capital Expenditures |
(0.01) | 0.00 | (0.03) | (0.01) | 0.33 | 0.66 | (0.02) | (0.02) | (0.03) | (0.01) |
Net Current Asset Value |
10.84 | 40.98 | 27.64 | 21.22 | 44.18 | 134.99 | 47.84 | (6.11) | (76.41) | (201.07) |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | — | — | (5.64) | (9.57) | 0.19 | 0.20 | 0.26 | 0.52 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | (18,820.98%) | (66,099.85%) | (102,334.51%) | (131,477.03%) | (176,193.60%) | (651,164.00%) |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.42 | 0.42 | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Cash ROIC |
(12.80%) | (5.74%) | (28.30%) | (46.03%) | (6.55%) | (17.98%) | (77.06%) | (71.35%) | (54.19%) | 103.94% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 91,860.45 | 65,015.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Average Receivables |
1.97 | 1.97 | 5.83 | 9.82 | 8.25 | 5.80 | 6.05 | 6.56 | 9.19 | 9.72 |
Average Payables |
— | — | 4.74 | 4.74 | 4.09 | 3.28 | 6.97 | 14.67 | 28.00 | 23.92 |
Average Assets |
28.09 | 6.34 | 17.07 | 30.23 | 37.89 | 93.92 | 99.23 | 79.34 | 143.72 | 122.80 |
Average Common Equity |
26.53 | 26.53 | 35.10 | 25.02 | 33.16 | 89.93 | 91.63 | 21.06 | (40.83) | (138.44) |
Columns are period end dates